Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

PSTV

Plus Therapeutics Inc

Dec 01 • 04:00PM ET

1.80

Dollar change +0.10
Percentage change 5.88	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-6.19	Insider Own	2.23%	Shs Outstand	4.52M	Perf Week	10.43%
Market Cap	8.14M	Forward P/E	-	EPS next Y	-2.37	Insider Trans	109.08%	Shs Float	4.42M	Perf Month	39.53%
Income	-15.16M	PEG	-	EPS next Q	-1.17	Inst Own	1.95%	Short Float / Ratio	4.87% / 0.31	Perf Quarter	-35.71%
Sales	3.75M	P/S	2.17	EPS this Y	58.10%	Inst Trans	-6.45%	Short Interest	0.22M	Perf Half Y	-54.20%
Book/sh	0.58	P/B	3.10	EPS next Y	51.14%	ROA	-83.36%	Target Price	17.50	Perf Year	-70.20%
Cash/sh	2.44	P/C	0.74	EPS next 5Y	-	ROE	-216.23%	52W Range	0.97 - 7.20	Perf YTD	-62.15%
Dividend	-	P/FCF	-	EPS past 5Y	82.03%	ROI	-553.43%	52W High	-75.00%	Beta	0.63
Dividend %	-	Quick Ratio	1.10	Sales past 5Y	-10.03%	Gross Margin	77.34%	52W Low	85.68%	ATR	0.23
Employees	17	Current Ratio	1.10	Sales Q/Q	1598.63%	Oper. Margin	-400.77%	RSI (14)	53.93	Volatility	9.92% 15.57%
Optionable	No	Debt/Eq	1.75	EPS Q/Q	65.02%	Profit Margin	-404.27%	Rel Volume	0.03	Prev Close	1.70
Shortable	Yes	LT Debt/Eq	0.05	Earnings	Oct 31 AMC	Payout	-	Avg Volume	688.95K	Price	1.80
Recom	1.00	SMA20	3.78%	SMA50	27.26%	SMA200	-38.03%	Volume	23,565	Change	5.88%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-25-21	Initiated	Ladenburg Thalmann	Buy	$8
Oct-16-20	Initiated	Maxim Group	Buy	$6

Nov-29-23 08:00AM	Plus Therapeutics to Present at the 5th Targeted Radiopharmaceuticals Summit Europe (GlobeNewswire) -5.56%
Nov-20-23 07:00AM	Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar (GlobeNewswire) -27.76%
Nov-15-23 07:00AM	Plus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023 (GlobeNewswire) +12.43%
Nov-13-23 09:31AM	Thinking about buying stock in Tivic Health Systems, Tigo Energy, TAT Technologies, Plus Therapeutics, or Acumen Pharmaceuticals? (PR Newswire)
Nov-03-23 07:00AM	Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda for the Treatment of Breast Cancer with Leptomeningeal Metastases (GlobeNewswire) +17.65%
09:29AM	Loading…
Nov-01-23 09:29AM	Plus Therapeutics, Inc. (NASDAQ:PSTV) Q3 2023 Earnings Call Transcript (Insider Monkey) +5.74%
Oct-31-23 04:10PM	Plus Therapeutics Announces Share Repurchase Program (GlobeNewswire) +10.92%
04:05PM	Plus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Oct-25-23 09:21AM	Plus Therapeutics to Present at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar (GlobeNewswire) -7.34%
Oct-23-23 04:05PM	Plus Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on October 31, 2023 (GlobeNewswire) -5.22%
Oct-10-23 07:00AM	Plus Therapeutics Completes Dosing in Cohort 4 of ReSPECT-LM Phase 1 Clinical Trial of Rhenium ( Re) Obisbemeda in Leptomeningeal Metastases (GlobeNewswire) +5.04%
Oct-09-23 07:00AM	Plus Therapeutics to Participate in the Jones Trading Healthcare Summit and ThinkEquity Conference in October (GlobeNewswire)
Sep-19-23 01:07PM	Targeted Cancer Treatment: Plus Therapeutics CEO Marc Hedrick, Live from NYSE (Exec Edge)
Sep-15-23 11:17AM	Director Howard Clowes Buys 6,993 Shares of Plus Therapeutics Inc (GuruFocus.com)
Sep-11-23 12:44PM	Plus Therapeutics Presents Cancer Treatment Data at Conference (Exec Edge) +8.70%
07:00AM	Loading…
07:00AM	Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference (GlobeNewswire)
Sep-08-23 12:49PM	Plus Therapeutics Expands Biocept Partnership with Diagnostic Platform (Exec Edge) -53.54%
11:18AM	Why Is Cancer Diagnostic Focused Biocept Stock Trading Higher Today? (Benzinga)
08:30AM	EXCLUSIVE: Cancer Firm Plus Therapeutics Licenses Diagnostic Assay To Detect Central Nervous System Cancers (Benzinga)
07:00AM	Plus Therapeutics Enters into License Agreement for Cerebrospinal Fluid Tumor Cell Enumeration Assay (GlobeNewswire)
Sep-05-23 01:13PM	Plus Therapeutics Trialing Cancer Treatment for Cerebrospinal Fluid (Exec Edge)
07:00AM	Plus Therapeutics Initiates Part B of ReSPECT-LM Phase 1/2a Trial for Leptomeningeal Metastase (GlobeNewswire)
Aug-30-23 07:00AM	Plus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-18-23 09:55AM	Plus (PSTV) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-15-23 10:58AM	Q2 2023 Plus Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-14-23 04:05PM	Plus Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Aug-11-23 06:28PM	Positive Results Unveiled for Targeted CNS Cancer Treatment in Recent Study by Plus Therapeutics (Exec Edge) -20.89%
08:00AM	EXCLUSIVE: Plus Therapeutics Lead Candidate Shows Preliminary Safety, Efficacy In Type Of Brain Cancer (Benzinga)
06:30AM	Plus Therapeutics Reports ReSPECT-LM Phase 1 Trial Data at the 2023 SNO/ASCO CNS Cancer Conference (GlobeNewswire)
Aug-08-23 04:05PM	Plus Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 14, 2023 (GlobeNewswire)
11:22AM	Loading…
11:22AM	Plus Therapeutics Announces Key Opinion Leader Roundtable on New Clinical Trial Data Being Presented at the 2023 SNO/ASCO CNS Cancer Conference (GlobeNewswire)
Aug-03-23 07:00AM	Plus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire)
Jul-27-23 05:34PM	Plus Therapeutics Appoints Dr. Pius Maliakal as VP of Clinical Operations (Exec Edge) -9.02%
04:05PM	Plus Therapeutics Strengthens Clinical Program with the Appointment of Pius Maliakal as Vice President of Clinical Operations (GlobeNewswire)
07:00AM	Plus Therapeutics to Present at the 2023 SNO/ASCO CNS Cancer Conference (GlobeNewswire)
Jul-13-23 07:00AM	Plus Therapeutics to Present at the 2nd Annual Targeted Radiopharmaceuticals Summit (GlobeNewswire)
Jun-29-23 07:00AM	Plus Therapeutics Reports Positive Interim Updates from Two ReSPECT Clinical Trials at SNMMI Annual Meeting (GlobeNewswire) -5.38%
Jun-14-23 07:00AM	Plus Therapeutics to Participate in the 2023 Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest (GlobeNewswire) -10.68%
Jun-08-23 07:00AM	Plus Therapeutics Announces Participation at Upcoming SNO Pediatric Conference and SNMMI Annual Meeting (GlobeNewswire)
Jun-01-23 07:00AM	Plus Therapeutics Provides Company Update Today (GlobeNewswire)
May-30-23 07:00AM	Plus Therapeutics Announces Topline Results from Recurrent Glioblastoma External Control Analysis at ASCO 2023 (GlobeNewswire) -7.19%
May-25-23 07:00AM	Plus Therapeutics to Present at the 2023 Virtual June Investor Summit (GlobeNewswire)
May-16-23 07:00AM	Plus Therapeutics Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire) -7.09%
May-12-23 07:00AM	Plus Therapeutics to Present in EndBrainCancer Initiative Virtual Educational Event (GlobeNewswire) -8.47%
May-02-23 07:00AM	Plus Therapeutics Expands Collaboration with Piramal Pharma Solutions to Meet Increase in Investigational Drug Demand for Ongoing and Planned Clinical Trials (GlobeNewswire) -7.27%
Apr-28-23 12:55PM	Plus Therapeutics Announces Reverse Stock Split (GlobeNewswire)
Apr-21-23 09:01AM	Q1 2023 Plus Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -13.98%
Apr-20-23 05:25PM	Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +5.83%
04:05PM	Plus Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Apr-19-23 07:00AM	Plus Therapeutics Completes Enrollment of the Original Three Patients Required for Cohort 8 of ReSPECT-GBM Phase 1/2a Trial (GlobeNewswire)
Apr-18-23 04:15PM	Plus Therapeutics to Participate in Panel at the Canaccord Genuity Horizons in Oncology Virtual Conference (GlobeNewswire)
07:00AM	Plus Therapeutics Completes Phase 1/Part A of the ReSPECT-LM Clinical Trial for Leptomeningeal Metastases (GlobeNewswire)
Apr-12-23 07:00AM	Plus Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on April 20, 2023 (GlobeNewswire)
Mar-28-23 07:00AM	Plus Therapeutics Successfully Treats First Patient in Cohort 8 of ReSPECT-GBM Phase 1/2a Trial (GlobeNewswire)
Mar-22-23 07:00AM	Plus Therapeutics Initiates Cohort 3 in Phase 1/Part A of the ReSPECT-LM Trial for Leptomeningeal Metastases (GlobeNewswire)
Feb-23-23 05:35PM	Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Plus Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (GlobeNewswire)
Feb-14-23 07:00AM	Plus Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023 (GlobeNewswire)
Feb-01-23 07:00AM	Plus Therapeutics Completes Enrollment in Second ReSPECT-LM Phase 1 Trial Cohort of Rhenium (¹Re) Obisbemeda for the Treatment of Leptomeningeal Metastases (GlobeNewswire) -8.29%
Jan-18-23 07:00AM	Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma (GlobeNewswire)
Jan-05-23 04:15PM	Plus Therapeutics: Targeting Brain Cancer with Rifle-Shot Precision (IPO-Edge.com)
Nov-21-22 06:53AM	Plus Therapeutics Highlights Updates On Lead Program In Brain Cancer Indications (Benzinga)
Nov-19-22 08:24AM	Plus Therapeutics Provides Updates on ReSPECT Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (GlobeNewswire)
Nov-02-22 07:00AM	Plus Therapeutics to Provide Update on ReSPECT Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (GlobeNewswire) -6.38%
Oct-26-22 07:00AM	Plus Therapeutics Announces Selection of Rhenium (186Re) Obisbemeda as International Non-Proprietary Name for 186RNL (GlobeNewswire)
Oct-20-22 04:05PM	Plus Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights (GlobeNewswire)
Oct-19-22 07:00AM	Plus Therapeutics Presents Preliminary Safety and Feasibility Data from ReSPECT-LM Clinical Trial at the European Association of Nuclear Medicine Congress (GlobeNewswire)
Oct-18-22 07:00AM	Plus Therapeutics to Present at the ThinkEquity Conference (GlobeNewswire) -6.77%
Oct-06-22 07:00AM	Plus Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on October 20, 2022 (GlobeNewswire) +14.69%
Oct-05-22 07:00AM	Plus Therapeutics Announces Patient Webinar in Recognition of Breast Cancer Awareness Month (GlobeNewswire)
Oct-04-22 07:15AM	Plus Therapeutics to Share Data in Oral Presentations from Ongoing ReSPECT Clinical Trials at the 35th Annual Congress of the European Association of Nuclear Medicine (GlobeNewswire) +5.34%
Sep-22-22 08:35AM	Why Are Plus Therapeutics Shares Gaining Today? (Benzinga)
07:00AM	Plus Therapeutics Executes $17.6 Million Award Contract with Cancer Prevention & Research Institute of Texas (GlobeNewswire)
Sep-12-22 07:00AM	Plus Therapeutics Presents Positive Phase 1 Data from ReSPECT-GBM Clinical Trial at the European Society for Medical Oncology Congress 2022 (GlobeNewswire) -11.44%
Sep-08-22 07:00AM	Plus Therapeutics to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Sep-06-22 07:00AM	Plus Therapeutics Announces FDA Meeting Summary for Lead Drug Candidate (GlobeNewswire) -12.14%
Aug-29-22 07:00AM	Plus Therapeutics Announces Summary of FDA Meeting on Companys cGMP Manufacturing Process for Lead Drug Candidate (GlobeNewswire) +14.55%
Aug-23-22 07:00AM	Plus Therapeutics to Present Data from ReSPECT-GBM Clinical Trial at the European Society for Medical Oncology Congress 2022 (GlobeNewswire) +10.16%
Aug-22-22 09:13AM	Funding wrap: Plus Therapeutics lands nearly $18M from CPRIT (American City Business Journals)
Aug-17-22 05:46PM	Plus Therapeutics Awarded $17.6 Million from State of Texas (GlobeNewswire)
Aug-15-22 08:37AM	Plus Therapeutics Shares Surge On Positive Data From Lead Brain Cancer Candidate (Benzinga) +7.36%
07:00AM	Plus Therapeutics Announces Share Repurchase Program (GlobeNewswire)
Aug-13-22 01:06PM	Plus Therapeutics Presents Positive Data from Ongoing ReSPECT Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases (GlobeNewswire)
Jul-28-22 07:00AM	Plus Therapeutics to Present Data from Ongoing ReSPECT Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases (GlobeNewswire)
Jul-27-22 07:00AM	Plus Therapeutics to Present at Inaugural Targeted Radiopharmaceuticals Summit (GlobeNewswire)
Jul-21-22 04:05PM	Plus Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights (GlobeNewswire)
Jul-13-22 07:00AM	Plus Therapeutics to Announce Second Quarter 2022 Financial Results and Host Conference Call on July 21, 2022 (GlobeNewswire)
Jul-12-22 07:00AM	Plus Therapeutics Successfully Completes Key Milestone for cGMP Manufacture of Lead Investigational Radiotherapeutic (GlobeNewswire)
Jun-22-22 07:30AM	Plus Therapeutics and Biocept Announce Comprehensive Laboratory Services Agreement for the ReSPECT-LM Trial (GlobeNewswire)
Jun-16-22 07:30AM	Plus Therapeutics Completes Enrollment of Cohort 1 ReSPECT-LM Phase 1/2a Trial (GlobeNewswire)
Jun-13-22 07:05AM	Plus Therapeutics Reports Positive Clinical Outcomes from ReSPECT-GBM Trial at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting (GlobeNewswire)
May-18-22 07:00AM	Plus Therapeutics to Present Virtually at the 2022 HC Wainwright Global Investment Conference (GlobeNewswire) -6.23%
Apr-26-22 07:00AM	Plus Therapeutics to Present at the 2022 Q2 Investor Summit (GlobeNewswire)
Apr-21-22 04:05PM	Plus Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights (GlobeNewswire)
Apr-19-22 07:00AM	Plus Therapeutics Announces Oral Presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting (GlobeNewswire)
Apr-14-22 07:00AM	Plus Therapeutics to Announce First Quarter 2022 Financial Results and Host Conference Call on April 21, 2022 (GlobeNewswire)
Apr-08-22 04:05PM	Plus Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Apr-05-22 07:00AM	Plus Therapeutics and Medidata Announce Expanded Clinical Trial Partnership (GlobeNewswire)
Mar-23-22 07:00AM	Plus Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest (GlobeNewswire)
Mar-22-22 07:00AM	Plus Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of 186RNL Radiotherapeutic for Leptomeningeal Metastases (GlobeNewswire)

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lenk Robert P	Director	Nov 16	Buy	1.95	1,000	1,950	25,160	Nov 17 07:00 AM
Lenk Robert P	Director	Nov 15	Buy	1.77	1,000	1,770	24,160	Nov 17 07:00 AM
Lenk Robert P	Director	Nov 13	Buy	1.43	4,000	5,720	23,160	Nov 15 07:00 AM
Lenk Robert P	Director	Nov 10	Buy	1.45	2,000	2,900	19,160	Nov 15 07:00 AM
Lenk Robert P	Director	Nov 09	Buy	1.59	4,199	6,676	17,160	Nov 13 07:00 AM
Lenk Robert P	Director	Nov 08	Buy	1.65	5,000	8,250	12,961	Nov 13 07:00 AM
Lenk Robert P	Director	Nov 07	Buy	1.64	6,000	9,840	7,961	Nov 08 07:00 AM
Lenk Robert P	Director	Nov 06	Buy	1.50	1,395	2,092	1,961	Nov 08 07:00 AM
Clowes Howard	Director	Sep 13	Buy	1.43	6,993	10,022	11,693	Sep 15 07:00 AM
Petersen Greg	Director	Sep 11	Buy	1.70	20,000	34,062	24,166	Sep 12 07:00 AM
Clowes Howard	Director	Jun 06	Buy	3.98	1,000	3,980	4,700	Jun 08 07:00 AM
Clowes Howard	Director	May 03	Buy	3.64	2,500	9,102	3,700	May 04 07:00 AM
Hawkins Richard J	Director	Mar 03	Buy	1.00	1	1	1	Mar 06 07:40 PM
Lenk Robert P	Director	Dec 30	Sale	0.31	1,500	472	8,500	Jan 04 07:56 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PSTV

Plus Therapeutics Inc

Upgrade your FINVIZ experience